Navigation Links
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
Date:5/1/2008

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

"Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments," said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. "We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options."

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:

May 7, 2008; 12:00 p.m. ET

Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD:

Parental Impressions and Experiences

APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD

APA Oral Presentation Session # 28

Methylphenidate Transdermal System:

May 7, 2008; 12:00 p.m. ET

Long-Term Treatment Effects of the Methylphenidate Transdermal System in

Boys and Girls with ADHD

APA Poster Presentation # NR6-018

Guanfacine Extended Release:

May 7, 2008; 12:00 p.m. ET

Guanfacine Extended Release: Duration of Effect in Children and

Adolescents Aged 6 to 17 Years With ADHD

APA Poster Presentation # NR6-008

May 7, 2008; 12:00 p.m. ET

Response to Guanfacine Extended Release in Children and Adolescents Aged 6

to 17 Years With ADHD

APA Poster Presentation # NR6-040

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Approximately 7.8 percent of all school-aged children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of U.S. adults aged 18-44 based on results from the National Comorbidity Survey Replication, a nationally representative household survey, which used a lay-administered diagnostic interview to assess a wide range of DSM-IV disorders. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further information please contact:

Porter Novelli for Shire:

Lucia Lodato

Lucia.Lodato@porternovelli.com

212.601.8037

917.617.3058 (on site at the meeting)

Lauren Plate

Lauren.Plate@porternovelli.com

212.601.8188

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
2. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
5. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
6. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
7. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ORANGE COUNTY, Calif. , April 29, 2016 ... technology industry is projected to shift from systems ... can replace all types of modality CRT Medical ... set-up." Although there are a host of foreseeable ... a serious concern; will existing modalities have to ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology:
(Date:5/2/2016)... Milford, PA (PRWEB) , ... May 02, 2016 , ... ... now available at MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. “Patients ... the office, have their unwanted fat treated and go home or back to work ...
(Date:5/1/2016)... (PRWEB) , ... May 02, 2016 , ... ... search for original 1968 Jimi Hendrix Merriweather Post Pavilion in Columbia, Maryland concert ... Hendrix concert poster. The concert was held on August 16. According to Hawley, ...
(Date:5/1/2016)... ... , ... Good Circle Insurance Agency of Mission Viejo, California recently introduced a ... verity of health, life and injury policies and this new plan allows coverage for ... insurance plans don’t cover chiropractic care, so we decided to create this new plan ...
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April ... veterinarians’ global impact on public health. The World Veterinary Association (WVA) and the ... year have selected continuing education with a One Health focus, which emphasizes how ...
(Date:4/29/2016)... ... April 30, 2016 , ... ... products, announces the Pick Up Springboard, an automotive invention that improves the storage ... industry is worth $162 billion," says Scott Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):